February 24, 2026 - 18:27

SUNRISE, Fla., Feb. 24, 2026 – Transpire Bio Inc., a clinical-stage biopharmaceutical firm dedicated to creating inhaled therapeutics for pulmonary and systemic conditions, has announced the strategic appointment of R. LaDuane Clifton as its new Chief Financial Officer. This move signals a pivotal step in the company's evolution.
The appointment comes as Transpire Bio advances its pipeline of innovative inhaled therapies, positioning itself for a transition toward commercialization. Clifton brings extensive financial leadership experience in the life sciences sector, with a proven track record in corporate finance, strategic transactions, and guiding companies through critical growth phases.
Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio, commented on the strategic hire, stating, "As we continue to progress from a clinical-stage to a commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth. LaDuane's deep expertise in financial strategy and capital markets will be invaluable as we execute on our mission to bring transformative inhaled treatments to patients."
In his new role, Clifton will oversee all financial operations, including corporate strategy, financial planning, investor relations, and capital allocation. His leadership is expected to be instrumental in building the financial infrastructure required to support Transpire Bio's expanding research and development programs and future commercial initiatives. The company is focused on addressing significant unmet medical needs through its proprietary inhalation technology platform.
November 22, 2026 - 00:48
Nasdaq Starts Charging for Financial Crime AI Agents as 850 Customers Sign OnNasdaq is taking a significant step by implementing fees for its artificial intelligence agents designed to combat financial crime. This move comes as the company seeks to expand its offerings in...
November 21, 2026 - 04:20
Key Insights for Long-Term Investors in GlobantGlobant`s recent shift to outcome-based pricing has shown promising results, particularly in its impact on gross margins. This new pricing strategy has already lifted gross margins by approximately...
November 20, 2026 - 02:05
Docusign to Release Third Quarter Financial Results on December 3, 2026Docusign has announced that it will share its financial results for the third quarter of fiscal 2027 after the U.S. markets close on Thursday, December 3, 2026. Following the release, the company...
November 19, 2026 - 01:35
Royal Gold Expands Board with Mining Veteran Harry Kenyon-SlaneyDENVER, November 18, 2026--Royal Gold has taken a significant step in enhancing its leadership by appointing Harry Kenyon-Slaney to its Board of Directors. Kenyon-Slaney brings a wealth of...